Completed PHASE4 INTERVENTIONAL NCT00261079

Fexofenadine in Pruritic Skin Disease

The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease

Sponsor: Handok Inc.

Conditions Pruritus

Interventions Fexofenadine

Updated 7 times since 2017 Last updated: Nov 5, 2007 Started: Apr 30, 2005 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pruritus, this trial is completed. The trial is conducted by Handok Inc. and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jul 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jul 2019 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Handok Inc.

Data source: Handok Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea